KOSDAQ pharmas superior to KOSPI ones in SG&A expenses growth rate

Last year, KOSDAQ listed pharmaceutical companies had a higher increase of SG&A(selling, general and administrative) expenses than the KOSPI listed pharmaceutical companies’ increase on average. In the 4^th quarter after the Kim Young-Ran Law was enforced, the company in the KOSPI recorded a negative growth rate from the one in the 3^rd quarter while the company in the KOSDAQ had a 10% increase.